Cancer Care Ontario | Cancer Care Ontario

niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

niraparib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Mar 2025

Drug

niraparib

Other Name(s): Zejula

Quick Link(s): Drug Monograph, Patient Info Sheet

Mar 2025

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Mar 2025

Guidelines and Advice

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Status: Current

Mar 2025

Regimen

VORA

Cancer Type:

Central Nervous System

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative, Palliative

Drugs Used:

vorasidenib (Unfunded)

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Mar 2025

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Status: Current
ID: PET 2024-1

Mar 2025

CISPVNBL(RT)

CRBPVNBL

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2017

Performance of Needle Biopsy of the Prostate for Men with Suspected or Established Prostate Cancer

NIRP

niraparib

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

VORA

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Pages